Complejo Asistencial Universitario de Leon

Running trials

• Recruiting

  Heart Failure in Women: Epidemiological and Prognostic Insights

  NCT07847983· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Source

• Active, not recruiting

  Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

  NCT06282978· Phase 2· Source

• Recruiting

  NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

  NCT05558319· Phase 3· Source

• Recruiting

  Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

  NCT05673681· Source

• Active, not recruiting

  Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

  NCT03742297· Phase 3· Source

• Recruiting

  Thoracic Tumours Register

  NCT02941458· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Atrial fibrillation1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  DESTINY Breast Respond HER2-(Ultra)Low Europe

  NCT05945732· Source

• Completed

  Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05014815· Phase 2· Source

• Completed

  ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

  NCT04603183· Phase 2· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Source

• Completed

  Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

  NCT03268954· Phase 3· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Source

• Completed

  Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

  NCT02448420· Phase 2· Source